Adjuncts and alternatives to oxime therapy in organophosphate poisoning--is there evidence of benefit in human poisoning? A review.
Organophosphate poisoning is common in developing countries. The morbidity and mortality with organophosphate poisoning is relatively high despite the use of atropine as specific antidotal therapy and oximes to reactivate acetylcholinesterase. Several adjunct and alternative therapies have been explored in animal and human studies. We reviewed the literature to ascertain if there was evidence of benefit of such therapies. Adjunct and alternative therapies included treatments to reduce poison absorption by topical application of creams, enhance toxin elimination by haemoperfusion or bioremediation and neutralise the poison by scavenging free organophosphate with cholinesterase-rich human plasma. In addition, magnesium, clonidine, diazepam, N-acetyl cysteine and adenosine receptor agonists have also been used to counteract poison effects. Detailed assessment was limited by the paucity of trials on adjunct/alternative therapies. The limited evidence from the review process suggested potential benefit from the use of human plasma infusion, early initiation of haemoperfusion and intravenous magnesium, in addition to standard therapy with atropine and pralidoxime. There appeared to be no additional benefit with alkalinisation or use of glycopyrrolate instead of atropine in human trials. Diazepam administration has been advocated by military authorities if symptoms developed following exposure to organophosphate. Bioremediation, clonidine, N-acetyl cysteine and adenosine receptor agonists have been evaluated only in animal models. The impact of adjunct and alternate therapies on outcomes in human poisoning needs to be further explored before implementation as standard treatment.
Peter
J V
JV
Department of Medical Intensive Care, Christian Medical College and Hospital, Vellore, India.
Moran
J L
JL
Pichamuthu
K
K
Chacko
B
B
D000818:Animals; D000931:Antidotes / Q000627:therapeutic use*; D018680:Cholinergic Antagonists / Q000627:therapeutic use; D002801:Cholinesterase Reactivators / Q000627:therapeutic use; D006801:Humans; D062025:Organophosphate Poisoning; D009943:Organophosphorus Compounds / Q000037:antagonists & inhibitors / Q000493:pharmacokinetics; D010091:Oximes / Q000627:therapeutic use*; D011041:Poisoning / Q000188:drug therapy*
D000931:Antidotes; D018680:Cholinergic Antagonists; D002801:Cholinesterase Reactivators; D009943:Organophosphorus Compounds; D010091:Oximes